<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087997</url>
  </required_header>
  <id_info>
    <org_study_id>4783-04</org_study_id>
    <nct_id>NCT00087997</nct_id>
  </id_info>
  <brief_title>A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an experimental&#xD;
      study drug (STA-4783) combined with an approved cancer medicine, paclitaxel, in the treatment&#xD;
      of soft tissue sarcomas. Paclitaxel (TaxolÂ®) has been approved and used in the United States&#xD;
      since 1992.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STA-4783 is a taxane potentiator, enhancing the effect of antitumor response of paclitaxel.&#xD;
      In an attempt to improve efficacy, paclitaxel is sometimes used in combination with other&#xD;
      anticancer agents. When paclitaxel is combined with other anticancer agents, although&#xD;
      response rate is usually increased, side effects are usually increased as well. There is an&#xD;
      urgent need for agents that can enhance the antitumor effects of paclitaxel without further&#xD;
      increasing undesirable side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date>October 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-4783</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be 18 years of age or older with histologic diagnosis of soft tissue sarcoma&#xD;
&#xD;
          -  Must have disease not suitable for curative resection&#xD;
&#xD;
          -  Must have failed &gt;1 first line treatment with evidence of progression. Adjuvant&#xD;
             therapy does not count as 1st line therapy unless recurrence occurs within 6 months of&#xD;
             administration&#xD;
&#xD;
          -  Must have ability to understand and the willingness to sign a written informed consent&#xD;
             document&#xD;
&#xD;
          -  Must have Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 2&#xD;
&#xD;
          -  Must have measurable disease according to Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) criteria&#xD;
&#xD;
          -  At least 4 weeks have passed since the last chemotherapy, immunotherapy, or radiation&#xD;
             therapy&#xD;
&#xD;
          -  There must be measurable disease outside the radiotherapy fields or progression of the&#xD;
             indicator lesions within the field since the completion of the radiotherapy&#xD;
&#xD;
          -  Must have a life expectancy of greater than 12 weeks&#xD;
&#xD;
          -  Must have clinical laboratory values at screening as defined below:&#xD;
&#xD;
          -  Hemoglobin &gt;9 g/dL,&#xD;
&#xD;
          -  Absolute neutrophil count &gt;1500/mm3,&#xD;
&#xD;
          -  Platelet count &gt;100,000/mm3,&#xD;
&#xD;
          -  Creatinine &lt;1.5 X ULN,&#xD;
&#xD;
          -  Bilirubin &lt;1.5 X ULN,&#xD;
&#xD;
          -  Asparate aminotransferase and alanine aminotransferase &lt;2.5 X ULN (&lt;5 X ULN in&#xD;
             presence of liver metastases)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients of childbearing potential not using or not willing to use a barrier method of&#xD;
             contraception&#xD;
&#xD;
          -  Prior malignancy other than soft tissue sarcoma (STS) within the last 5 yrs with the&#xD;
             exception of:&#xD;
&#xD;
               -  Adequately treated in situ carcinoma of the cervix uteri;&#xD;
&#xD;
               -  Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Presence of a clinically significant and uncontrolled infection&#xD;
&#xD;
          -  Presence of &gt;Grade 2 neuropathy&#xD;
&#xD;
          -  Symptomatic central nervous system metastases within last 8 weeks or on&#xD;
             corticosteroids for CNS symptom management&#xD;
&#xD;
          -  Presence of clinically significant arrythmias&#xD;
&#xD;
          -  Presence of a serious concurrent illness or other conditions (e.g., psychological,&#xD;
             family, sociological, or geographical circumstances) that do not permit adequate&#xD;
             follow-up and compliance with the protocol&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to taxanes or cremaphore in spite of&#xD;
             premedication&#xD;
&#xD;
          -  Use of any investigational agents within 4 weeks prior to the first dose of study&#xD;
             drug(s)&#xD;
&#xD;
          -  Major surgery within 2 weeks of screening&#xD;
&#xD;
          -  Radiation treatment in past &gt;25% of bone marrow&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Department of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Med. Center (Wichita CCOP)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Hurley Cancer Institute</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute Clinical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Blumenthal Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>July 19, 2004</study_first_submitted>
  <study_first_submitted_qc>July 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2004</study_first_posted>
  <last_update_submitted>June 19, 2006</last_update_submitted>
  <last_update_submitted_qc>June 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2006</last_update_posted>
  <keyword>sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

